Common TitleTMB-301
Official Title A Phase 3, Single Arm, 24-Week, Multicenter Study of Ibalizumab Plus an Optimized Background Regimen (OBR) in Treatment-Experienced Patients Infected With Multi-Drug Resistant HIV-1
Phase Phase III
ClinicalTrials.gov NCT02475629
Treatments
Ibalizumab
Ibalizumab
Tradename:TrogarzoOther Names:IBAClass:Entry InhibitorsCategories Resistance/Virological FailureTreatment-Experienced
Funding
IndustryTaiMed Biologics Inc.
References
- Emu B, Fessel J, Schrader S, et al. Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1. N Engl J Med. 2018;379:645-54.